Palliative CareNCT02651805
Mechanical Insufflator-exsufflator to Control Mucus Hypersecretion in Patients in Palliative Care - A Feasibility Study
A study testing Mechanical Insufflation-Exsufflation in people with Palliative Care and Mucus Hypersecretion, run by Universidade Federal de Sao Carlos at 1 site in Brazil.
Trial summary
Patients with advanced chronic diseases may suffer with respiratory secretion and available therapies to control this condition are uncomfortable or little effective in palliative care patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Palliative Care, Mucus Hypersecretion
- What is being tested?
- Mechanical Insufflation-Exsufflation
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteBrazil
- Study dates
- Feb 2016to 30 Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Prognosis:
- Less than one year assessed by the responsible physician, with a negative answer of the to the "surprise question" - Would you be surprised if this patient died in the following year?
- Higher than 3 months, assessed by the same physician
- Patients with problems to deal with secretions, which could be one or both of the following problems:
- Hypersecretion
- Cough inefficiency (peak cough flow <250L/min)
- Karnofsky Performance Status Scale higher or equal to 30%;
- Ability to give written informed consent or presence of a person who is responsable for the patient
Who cannot join
- Patients with conditions considered as contra-indication for the use of Mechanical Insufflator-Exsufflator:
- Bullous emphysema history
- Known susceptibility for pneumothorax or pneumo-mediastinum
- Known to have had any recent barotrauma.
Trial locations and contacts
1 site in 1 country.
Brazil1 site, 1 recruiting
- Recruiting
Hospital Estadual Américo Brasiliense
São Carlos, São Paulo
Juliano F Arcuri, MSc, +55 16 33518343, julianoarcuri@gmail.com
About this study
Official title: Mechanical Insufflator-exsufflator to Manage Respiratory Secretion in Patients in Palliative Care - A Feasibility Study
Patients with advanced chronic diseases may suffer with respiratory secretion and available therapies to control this condition are uncomfortable or little effective in palliative care patients. Therefore, alternative therapies should be tested, assessing clinically relevant outcomes in palliative care, such as comfort during therapy and the number of interventions required in a day. Mechanical Insufflation-Exsufflation is an option that presents advantages, since it can be used in patients with minimum cooperation and is non-invasive, which may lead to higher comfort during therapy.
The aim of the study is to verify the feasibility of a clinical trial comparing the effects of Mechanical Insufflation-Exsufflation with usual care in hospitalized palliative care patients that are suffering with respiratory secretion. Patients allocation will follow a "fast-track allocation design", in which included patients will be randomized in two groups:
Read more
- Receive Mechanical Insufflation-Exsufflation therapy in the moment that is assigned to this group;
- will receive 24h of usual care and after that will be allowed to choose between usual care or Mechanical Insufflation-Exsufflation Therapy.
The assessments will be: Time from the first intervention until the need of a following intervention, discomfort due therapy, discomfort due respiratory secretion, palliative outcome scale, number of adverse events and number of interventions during 24h period. The primary outcome is to verify the feasibility of developing a future larger clinical trial to assess the effects of the use of Mechanical Insufflation-Exsufflation to control respiratory secretions in patients in palliative care.
Read the detailed description
Investigators will conduct a feasibility study for a future fast track randomized trial, which will be carried out in the Américo Brasiliense State Hospital and conducted by the Spirometry and Respiratory Physiotherapy Laboratory from the Federal University of São Carlos, Brazil.
The concept of feasibility is defined as "capable of being done or carried out" and studies which aim is to verify the feasibility intends to verify if a larger clinical trial would have a acceptable probability of success in proving the efficacy of an intervention 24. The importance of feasibility studies has been discussed since health research resources are frequently wasted in large clinical trials with interventions with small impact, studies with insufficient power, or even using measures and outcomes that do not reflect the expected changes caused by the interventions. Furthermore, these studies are essential when dealing with populations that usually lead to an increased chance of losing the follow-up or a high number of missing data, such as palliative care.
Both groups will receive the therapy with the mechanical insufflators-exsufflator, however, the Mechanical insufflation-exsufflation group will receive it as in a fast track way, while the usual care, will receive the usual care for more 24 hours, and then they will receive one session of Mechanical Insufflation-Exsufflation. After this 24 hours period, the patients will be asked what therapy they would like to receive each time they need help to deal with hypersecretion until the end of the hospitalization, or until the physician responsible for the patient consider the hypersecretion was controlled.
The allocation through fast track has been used due to ethical reasons, in order to maintain the randomized and controlled aspects of the research, and yet provide the opportunity to all patients to be benefited of the new intervention before the end of the study. Furthermore, an increase in the acceptability and retention of the participants is expected, since they are going to receive the new therapy in some moment of the study, which may be during or after the follow-up 28. The cross-over design was not chosen, since the wash-out period necessary to this model of study might lead to a period without treatment for vulnerable patients, with expected short life time.
Usual Care The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
Mechanical Insufflation-Exsufflation The settings used in the Mechanical Insufflator-Exsufflator will be the same of a previous study, where were used: six assisted cough cycles with pressures of 40 to -40cmH2O; the inspiratory time of 3s; the expiratory time 4s and a pause between cycles of 4s. The patients will be instructed to cough alongside the exsufflation phase, with exception of Chronic Obstructive Pulmonary Disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it.
- Conditions
- Palliative Care, Mucus Hypersecretion
- Being tested
- Mechanical Insufflation-Exsufflation, Usual Care
- Keywords
- Palliative Care, Respiratory Secretion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mechanical Insufflation-ExsufflationDevice
Also called Cough Assist (Philips Respironics)
Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
Usual CareOther
The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
| Study group | Role | What they receive |
|---|---|---|
| Mechanical Insufflation-Exsufflation Group | Experimental | Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation Receives: Device: Mechanical Insufflation-Exsufflation |
| Usual Care Group | Active comparator | Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart Receives: Device: Mechanical Insufflation-Exsufflation; Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study Feasibility assessed by verifying the recruitment rates, acceptability of the patients and hospital
The feasibility of the study will be the primary outcome, and it will be assessed by verifying the recruitment rates, acceptability of the patients and hospital, and if the assessments were suitable to the study
Measured: Through the completion of the study, up to one year
Secondary outcomes (6)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Assessed by the number of times an event with change in physiological parameters occurred during the intervention (Heart Rate>150bpm or <50bpm; Systolic Blood Pressure>200mmHg or <80mmHg; decrease of 5% or higher in the pulse oxymetry; hemoptysis).
Measured: Assessed in the period between the start of the intervention until 30min after the end of the intervention
Effect size of Palliative Outcome Scale
This is a quality of life multidimensional scale in patients in palliative care. With this scale, we intend to see the effects of the therapy over the general perceived health of the patients.
Measured: Immediately after the inclusion and in the final assessment (24 hours after the inclusion).
Effect size of discomfort due to the hypersecretion
Assessed using a numeric scale (0-10). This assessment will be conducted in order to evaluate how much the hypersecretion bothers the patient, and if the therapy is capable of changing this perception of discomfort.
Measured: Immediately before the first intervention and ten minutes after the first intervention.
Effect size of discomfort due to the therapy
Assessed using a numeric scale (0-10), this assessment will provide information to the decision of the viability the therapy in palliative care, since uncomfortable therapies are often discouraged since usually they may not cure the cause of the problem.
Measured: Ten minutes after the first intervention
Effect size of time until the next intervention
The moment immediately after the first intervention until the time a new intervention is required. It will be verified in the patient's records. The therapies to control hypersecretions may lead to discomfort due to the stimulation of the cough and the change in the respiratory pattern, a therapy with a more lasting effect may be preferable, since it can provide a longer period without the discomfort of another intervention.
Measured: In the end of the 24 hours period.
Effect size of number of interventions during 24 hours
The number of interventions will be verified in the patient's records. Therapies that may lead to a lasting effect, can be performed less times during a day, this reflects in a longer period of comfort, and smaller health expenses.
Measured: In the end of the 24 hours period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2016 (estimated)
- Study startFeb 2016
- Primary completion30 Jul 2017 (estimated)
- Study completion30 Jul 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Palliative CareStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidade Federal de Sao Carlos
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Estadual Américo Brasiliense, Philips Respironics
- Responsible party
- Principal investigator, Juliano Ferreira Arcuri, Universidade Federal de Sao Carlos
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02651805
- Sponsor's protocol ID
- MIE-Palliative
- Status last verified
- Jul 2017
- First submitted
- 16 Dec 2015
- Last updated
- 18 Jul 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest. 1993 Nov;104(5):1553-62. doi: 10.1378/chest.104.5.1553.
PubMed 8222823Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS. Chest. 2002 Jul;122(1):92-8. doi: 10.1378/chest.122.1.92.
PubMed 12114343
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanical Insufflator-exsufflator to Manage Respiratory Secretion in Patients in Palliative Care - A Feasibility Study
- ClinicalTrials.gov ID
- NCT02651805
- Acronym / sponsor ID
- MIE-Palliative
- Conditions
- Palliative Care, Mucus Hypersecretion
- Keywords
- Palliative Care, Respiratory Secretion
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Universidade Federal de Sao CarlosUniversity, hospital or other
- Collaborators
- Hospital Estadual Américo Brasiliense, Philips Respironics
- Study start
- Feb 2016 (actual)
- Primary completion
- 30 Jul 2017 (estimated)
- Study completion
- 30 Jul 2017 (estimated)
- First posted
- 11 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with advanced chronic diseases may suffer with respiratory secretion and available therapies to control this condition are uncomfortable or little effective in palliative care patients. Therefore, alternative therapies should be tested, assessing clinically relevant outcomes in palliative care, such as comfort during therapy and the number of interventions required in a day. Mechanical Insufflation-Exsufflation is an option that presents advantages, since it can be used in patients with minimum cooperation and is non-invasive, which may lead to higher comfort during therapy.
The aim of the study is to verify the feasibility of a clinical trial comparing the effects of Mechanical Insufflation-Exsufflation with usual care in hospitalized palliative care patients that are suffering with respiratory secretion. Patients allocation will follow a "fast-track allocation design", in which included patients will be randomized in two groups:
- Receive Mechanical Insufflation-Exsufflation therapy in the moment that is assigned to this group;
- will receive 24h of usual care and after that will be allowed to choose between usual care or Mechanical Insufflation-Exsufflation Therapy.
The assessments will be: Time from the first intervention until the need of a following intervention, discomfort due therapy, discomfort due respiratory secretion, palliative outcome scale, number of adverse events and number of interventions during 24h period. The primary outcome is to verify the feasibility of developing a future larger clinical trial to assess the effects of the use of Mechanical Insufflation-Exsufflation to control respiratory secretions in patients in palliative care.
Detailed description
Investigators will conduct a feasibility study for a future fast track randomized trial, which will be carried out in the Américo Brasiliense State Hospital and conducted by the Spirometry and Respiratory Physiotherapy Laboratory from the Federal University of São Carlos, Brazil.
The concept of feasibility is defined as "capable of being done or carried out" and studies which aim is to verify the feasibility intends to verify if a larger clinical trial would have a acceptable probability of success in proving the efficacy of an intervention 24. The importance of feasibility studies has been discussed since health research resources are frequently wasted in large clinical trials with interventions with small impact, studies with insufficient power, or even using measures and outcomes that do not reflect the expected changes caused by the interventions. Furthermore, these studies are essential when dealing with populations that usually lead to an increased chance of losing the follow-up or a high number of missing data, such as palliative care.
Both groups will receive the therapy with the mechanical insufflators-exsufflator, however, the Mechanical insufflation-exsufflation group will receive it as in a fast track way, while the usual care, will receive the usual care for more 24 hours, and then they will receive one session of Mechanical Insufflation-Exsufflation. After this 24 hours period, the patients will be asked what therapy they would like to receive each time they need help to deal with hypersecretion until the end of the hospitalization, or until the physician responsible for the patient consider the hypersecretion was controlled.
The allocation through fast track has been used due to ethical reasons, in order to maintain the randomized and controlled aspects of the research, and yet provide the opportunity to all patients to be benefited of the new intervention before the end of the study. Furthermore, an increase in the acceptability and retention of the participants is expected, since they are going to receive the new therapy in some moment of the study, which may be during or after the follow-up 28. The cross-over design was not chosen, since the wash-out period necessary to this model of study might lead to a period without treatment for vulnerable patients, with expected short life time.
Usual Care The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
Mechanical Insufflation-Exsufflation The settings used in the Mechanical Insufflator-Exsufflator will be the same of a previous study, where were used: six assisted cough cycles with pressures of 40 to -40cmH2O; the inspiratory time of 3s; the expiratory time 4s and a pause between cycles of 4s. The patients will be instructed to cough alongside the exsufflation phase, with exception of Chronic Obstructive Pulmonary Disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mechanical Insufflation-Exsufflation Group | Experimental | Device: Mechanical Insufflation-ExsufflationPatients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation |
| Usual Care Group | Active comparator | Device: Mechanical Insufflation-Exsufflation, Other: Usual CarePatients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Prognosis:
- Patients with problems to deal with secretions, which could be one or both of the following problems:
- Karnofsky Performance Status Scale higher or equal to 30%;
- Ability to give written informed consent or presence of a person who is responsable for the patient
Key exclusion criteria (4 listed)
- Patients with conditions considered as contra-indication for the use of Mechanical Insufflator-Exsufflator:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mechanical Insufflation-ExsufflationAlso: Cough Assist (Philips Respironics)Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions. | Device | Mechanical Insufflation-Exsufflation Group, Usual Care Group |
| Usual CareThe patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions. | Other | Usual Care Group |
Primary outcome
Study Feasibility assessed by verifying the recruitment rates, acceptability of the patients and hospital
Time frame: Through the completion of the study, up to one year
The feasibility of the study will be the primary outcome, and it will be assessed by verifying the recruitment rates, acceptability of the patients and hospital, and if the assessments were suitable to the study
6 secondary outcomes
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Time frame: Assessed in the period between the start of the intervention until 30min after the end of the intervention
Effect size of Palliative Outcome Scale
Time frame: Immediately after the inclusion and in the final assessment (24 hours after the inclusion).
Effect size of discomfort due to the hypersecretion
Time frame: Immediately before the first intervention and ten minutes after the first intervention.
Effect size of discomfort due to the therapy
Time frame: Ten minutes after the first intervention
Effect size of time until the next intervention
Time frame: In the end of the 24 hours period.
Effect size of number of interventions during 24 hours
Time frame: In the end of the 24 hours period
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2017.
- Background: PubMed 8222823Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest. 1993 Nov;104(5):1553-62. doi: 10.1378/chest.104.5.1553.
- Background: PubMed 12114343Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS. Chest. 2002 Jul;122(1):92-8. doi: 10.1378/chest.122.1.92.
- Individual participant dataSharing planned: Undecided
Related trials for Palliative Care
Not yet recruitingPhase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1/2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Malignant Solid Neoplasm
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruiting
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Solid Tumor
Enrolling by invitationPhase 3
Nudging Effective and Equitable Delivery of Specialty Palliative Care
Serious Illness, Palliative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mechanical Insufflation-Exsufflation in people with Palliative Care and Mucus Hypersecretion, run by Universidade Federal de Sao Carlos at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Juliano F Arcuri, MSc (+55 16 33518343, julianoarcuri@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Study Feasibility assessed by verifying the recruitment rates, acceptability of the patients and hospital (time frame: Through the completion of the study, up to one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02651805, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2017.